FindMyKOL
Clinical trialNCT05711615RecruitingPhase 1Interventional

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

NCT05711615 is a phase 1 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is recruiting participants. It studies Doxorubicin and Nedisertib in Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma and 10 more conditions. The registry lists an enrollment of 30 participants at 16 sites in 1 country. The registry lists a start date of 6 Feb 2024 and a primary completion date of 3 May 2027. One of its registered investigators has a FindMyKOL profile.

SponsorNational Cancer Institute (NCI) →Enrollment30Metastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic MyxofibrosarcomaMetastatic SarcomaMetastatic Synovial SarcomaMetastatic Undifferentiated Pleomorphic Sarcoma+6 more conditions
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05711615
FieldValue
Registry IDNCT05711615
StatusRecruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorNational Cancer Institute (NCI)
Enrollment30
Registered sites16
Countries1
ConditionsMetastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma and 6 more conditions
DrugsDoxorubicin and Nedisertib
Start6 Feb 2024
Primary completion3 May 2027
Study completion3 May 2027
Last update posted16 Nov 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States2 sites, 2 recruiting
  • Los Angeles General Medical Center

    Los Angeles

    Mark Agulnik
    Recruiting
  • Usc / Norris Comprehensive Cancer Center

    Los Angeles

    Mark Agulnik
    Recruiting
Colorado, United States1 site, 1 recruiting
  • Uchealth University of Colorado Hospital

    Aurora

    Breelyn A. Wilky
    Recruiting
Florida, United States1 site, 1 recruiting
  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami

    Emily E. Jonczak
    Recruiting
Illinois, United States3 sites
  • University of Chicago Comprehensive Cancer Center

    Chicago

    Active, not recruiting
  • Uc Comprehensive Cancer Center at Silver Cross

    New Lenox

    Active, not recruiting
  • University of Chicago Medicine-Orland Park

    Orland Park

    Active, not recruiting
Maryland, United States2 sites, 2 recruiting
  • Johns Hopkins University/sidney Kimmel Cancer Center

    Baltimore

    H. Catherine Wilbur
    Recruiting
  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda

    A P. Chen
    Recruiting
Massachusetts, United States1 site, 1 recruiting
  • Dana-Farber Cancer Institute

    Boston

    Candace L. Haddox
    Recruiting
Michigan, United States1 site
  • University of Michigan Rogel Cancer Center

    Ann Arbor

    Suspended
Missouri, United States2 sites, 2 recruiting
  • Siteman Cancer Center-South County

    St Louis

    Mia C. Weiss
    Recruiting
  • Washington University School of Medicine

    St Louis

    Mia C. Weiss
    Recruiting
Pennsylvania, United States1 site, 1 recruiting
  • Upmc Hillman Cancer Center

    Pittsburgh

    Melissa A. Burgess
    Recruiting
Texas, United States1 site, 1 recruiting
  • Ut Md Anderson Cancer Center

    Houston

    Michael S. Nakazawa
    Recruiting
Virginia, United States1 site, 1 recruiting
  • University of Virginia Cancer Center

    Charlottesville

    Paul V. Viscuse
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 1 siteMI1New YorkNYMassachusetts: 1 site, 1 recruitingMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 3 sitesIL3IndianaINOhioOHPennsylvania: 1 site, 1 recruitingPA1New JerseyNJConnecticutCTCalifornia: 2 sites, 2 recruitingCA2NevadaNVWyomingWYNebraskaNEMissouri: 2 sites, 2 recruitingMO2KentuckyKYWest VirginiaWVVirginia: 1 site, 1 recruitingVA1Maryland: 2 sites, 2 recruitingMD2DelawareDEArizonaAZUtahUTColorado: 1 site, 1 recruitingCO1KansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 site, 1 recruitingTX1Florida: 1 site, 1 recruitingFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Doxorubicin →Nedisertib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05711615

Each answer restates registry values shown on this page.

What is NCT05711615?

NCT05711615 is a phase 1 interventional trial sponsored by National Cancer Institute (NCI). It studies Doxorubicin and Nedisertib in Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma and 10 more conditions.

Is NCT05711615 recruiting?

As of 21 Nov 2026, it is recruiting participants. 12 of its 16 sites list their own status as recruiting.

Who leads NCT05711615?

The registry names Candace L Haddox (principal investigator, Dana-Farber - Harvard Cancer Center LAO) as the overall official.

Where does NCT05711615 run?

The registry lists 16 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05711615 study?

The registered drug and biological interventions are Doxorubicin and Nedisertib.

When is NCT05711615 expected to complete?

The registry lists a primary completion date of 3 May 2027 and a study completion date of 3 May 2027. The sponsor last updated the record on 16 Nov 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.